Australian Federal Budget delivers little for biotech…but there are a couple of bright spots
On the back of last year's savage Australian Budget cuts to industry support and science programs, the biotech industry can be relieved it was not again targeted for direct savings. However, nor does this year’s Federal Budget offer excitement for the industry in terms of innovation stimulus, according to trade group AusBiotech.
"Federal Budget 2015-16 is underwhelming apart from a few bright spots," said Anna Lavalle, chief executive of AusBiotech, adding:"Australia’s biotech companies are doing great work in growing jobs and revenue sources for the post-mining boom economy, but this Budget delivers no significant measures to encourage the commercialisation of life sciences innovation."
Medical Research Future Fund
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze